研究单位：[1]PegBio Co., Ltd.[2]First Hospital of Hebei Medical University[3]First People's Hospital of Chenzhou[4]Second Hospital of Jilin University[5]The First Affiliated Hospital of Shanxi Medical University[6]Tang-Du Hospital[7]People's Hospital of Xinjiang Uygur Autonomous Region[8]Affiliated Hospital of Hebei University[9]Qianfoshan Hospital[10]Beijing University People's Hospital[11]Qingdao Central Hospital[12]Changsha Central Hospital[13]Tianjin People's Hospital[14]ZhuZhou Central Hospital[15]The First Affiliated Hospital with Nanjing Medical University[16]Qiqihar First Hospital[17]Luoyang Central Hospital[18]Baotou Central Hospital[19]Zhejiang Province People's Hospital[20]Jingzhou Central Hospital[21]WuXi Central Hospital
研究目的：
This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 once-weekly subcutaneous doses of PB-119 to subjects with type 2 diabetes mellitus (T2DM) not well-controlled by metformin monotherapy.
